Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
05 07 2019
Historique:
received: 28 11 2018
accepted: 23 05 2019
entrez: 7 7 2019
pubmed: 7 7 2019
medline: 23 10 2019
Statut: epublish

Résumé

There has been a dramatic increase in the detection of lung nodules, many of which are preneoplasia atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) or invasive adenocarcinoma (ADC). The molecular landscape and the evolutionary trajectory of lung preneoplasia have not been well defined. Here, we perform multi-region exome sequencing of 116 resected lung nodules including AAH (n = 22), AIS (n = 27), MIA (n = 54) and synchronous ADC (n = 13). Comparing AAH to AIS, MIA and ADC, we observe progressive genomic evolution at the single nucleotide level and demarcated evolution at the chromosomal level supporting the early lung carcinogenesis model from AAH to AIS, MIA and ADC. Subclonal analyses reveal a higher proportion of clonal mutations in AIS/MIA/ADC than AAH suggesting neoplastic transformation of lung preneoplasia is predominantly associated with a selective sweep of unfit subclones. Analysis of multifocal pulmonary nodules from the same patients reveal evidence of convergent evolution.

Identifiants

pubmed: 31278276
doi: 10.1038/s41467-019-10877-8
pii: 10.1038/s41467-019-10877-8
pmc: PMC6611767
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2978

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : R01CA234629-01
Pays : International
Organisme : NIAMS NIH HHS
ID : T32 AR065971
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234629
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409 (2011).
doi: 10.1056/NEJMoa1102873
Detterbeck, F. C. & Homer, R. J. Approach to the ground-glass nodule. Clin. Chest Med. 32, 799–810 (2011).
doi: 10.1016/j.ccm.2011.08.002
Kodama, K. et al. Treatment strategy for patients with small peripheral lung lesion(s): intermediate-term results of prospective study. Eur. J. Cardiothorac. Surg. 34, 1068–1074 (2008).
doi: 10.1016/j.ejcts.2008.07.044
Mun, M. & Kohno, T. Efficacy of thoracoscopic resection for multifocal bronchioloalveolar carcinoma showing pure ground-glass opacities of 20 mm or less in diameter. J. Thorac. Cardiovasc. Surg. 134, 877–882 (2007).
doi: 10.1016/j.jtcvs.2007.06.010
Ohtsuka, T., Watanabe, K., Kaji, M., Naruke, T. & Suemasu, K. A clinicopathological study of resected pulmonary nodules with focal pure ground-glass opacity. Eur. J. Cardiothorac. Surg. 30, 160–163 (2006).
doi: 10.1016/j.ejcts.2006.03.058
Weichert, W. & Warth, A. Early lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma. Curr. Opin. Pulm. Med. 20, 309–316 (2014).
doi: 10.1097/MCP.0000000000000065
Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).
doi: 10.1016/j.cell.2012.04.023
Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809–813 (2009).
doi: 10.1038/nature08489
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
doi: 10.1056/NEJMoa1113205
Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356–361 (2011).
doi: 10.1038/nature09650
Zhang, J. et al. Intra-tumor heterogeneity in localized lung adenocarcinomas delineated by multi-region sequencing. Science 346, 256–259 (2014).
doi: 10.1126/science.1256930
Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
doi: 10.1056/NEJMoa1616288
de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251–256 (2014).
doi: 10.1126/science.1253462
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
doi: 10.1038/nature13385
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
doi: 10.1038/nature11252
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
doi: 10.1038/nature07385
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
doi: 10.1038/nature00766
Kim, S. et al. Deamination effects in formalin-fixed, paraffin-embedded tissue samples in the era of precision medicine. J. Mol. Diagn. 19, 137–146 (2017).
doi: 10.1016/j.jmoldx.2016.09.006
Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246–259 (2013).
doi: 10.1016/j.celrep.2012.12.008
de Bruin, E. C., McGranahan, N. & Swanton, C. Analysis of intratumor heterogeneity unravels lung cancer evolution. Mol. Cell. Oncol. 2, e985549 (2015).
doi: 10.4161/23723556.2014.985549
Venkatesan, S. et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Ann. Oncol. 29, 563–572 (2018).
doi: 10.1093/annonc/mdy003
Glaser, A. P. et al. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. Oncotarget 9, 4537–4548 (2018).
doi: 10.18632/oncotarget.23344
Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970–976 (2013).
doi: 10.1038/ng.2702
San Lucas, F. A. et al. Rapid and powerful detection of subtle allelic imbalance from exome sequencing data with hapLOHseq. Bioinformatics 32, 3015–3017 (2016).
doi: 10.1093/bioinformatics/btw340
Martincorena, I. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880–886 (2015).
doi: 10.1126/science.aaa6806
Izumchenko, E. et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat. Commun. 6, 8258 (2015).
doi: 10.1038/ncomms9258
Sivakumar, S. et al. Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma. Cancer Res. 77, 6119–6130 (2017).
doi: 10.1158/0008-5472.CAN-17-1605
Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121–1134 (2012).
doi: 10.1016/j.cell.2012.08.024
Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).
doi: 10.1038/ng.2891
Ko, J. P. & Azour, L. Management of Incidental Lung Nodules. Semin Ultrasound CT MR 39, 249–259 (2018).
doi: 10.1053/j.sult.2018.02.006
Massion, P. P. & Walker, R. C. Indeterminate pulmonary nodules: risk for having or for developing lung cancer? Cancer Prev. Res. 7, 1173–1178 (2014).
doi: 10.1158/1940-6207.CAPR-14-0364
McWilliams, A. et al. Probability of cancer in pulmonary nodules detected on first screening CT. N. Engl. J. Med. 369, 910–919 (2013).
doi: 10.1056/NEJMoa1214726
Tammemagi, M. C. et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. Lancet Oncol. 18, 1523–1531 (2017).
doi: 10.1016/S1470-2045(17)30597-1
Prasetyanti, P. R. & Medema, J. P. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol. Cancer 16, 41 (2017).
doi: 10.1186/s12943-017-0600-4
Quek, K. et al. DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget 8, 21994–22002 (2017).
doi: 10.18632/oncotarget.15777
Reuben, A. et al. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. Cancer Discov. 7, 1088–1097 (2017).
doi: 10.1158/2159-8290.CD-17-0256
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
doi: 10.1093/bioinformatics/btp324
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
doi: 10.1101/gr.107524.110
Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).
doi: 10.1101/gr.129684.111
Olshen, A. B., Venkatraman, E. S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557–572 (2004).
doi: 10.1093/biostatistics/kxh008
Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
doi: 10.1186/gb-2011-12-4-r41
Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).
doi: 10.1038/nbt.2203
Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910–16915 (2010).
doi: 10.1073/pnas.1009843107
Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014).
doi: 10.1038/nmeth.2883
McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med 7, 283ra254 (2015).
doi: 10.1126/scitranslmed.aaa1408
Paradis, E., Claude, J. & Strimmer, K. APE: analyses of phylogenetics and evolution in R language. Bioinformatics 20, 289–290 (2004).
doi: 10.1093/bioinformatics/btg412

Auteurs

Xin Hu (X)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Junya Fujimoto (J)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Lisha Ying (L)

Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, 310022, Hangzhou, China.

Junya Fukuoka (J)

Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 8528523, Nagasaki, Japan.

Kazuto Ashizawa (K)

Department of Clinical Oncology, Nagasaki University Graduate School of Biomedical Sciences, 8528523, Nagasaki, Japan.

Wenyong Sun (W)

Department of Pathology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, 310022, Hangzhou, China.

Alexandre Reuben (A)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Chi-Wan Chow (CW)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Nicholas McGranahan (N)

Cancer Research United Kingdom-University College London Lung Cancer Centre of Excellence, London, WC1E6BT, UK.

Runzhe Chen (R)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Jinlin Hu (J)

Department of Pathology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, 310022, Hangzhou, China.

Myrna C Godoy (MC)

Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Kazuhiro Tabata (K)

Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 8528523, Nagasaki, Japan.

Kishio Kuroda (K)

Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 8528523, Nagasaki, Japan.

Lei Shi (L)

Department of Radiology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, 310022, Hangzhou, China.

Jun Li (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Carmen Behrens (C)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Edwin Roger Parra (ER)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Latasha D Little (LD)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Curtis Gumbs (C)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Xizeng Mao (X)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Xingzhi Song (X)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Samantha Tippen (S)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Rebecca L Thornton (RL)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Humam Kadara (H)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Paul Scheet (P)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Emily Roarty (E)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Edwin Justin Ostrin (EJ)

Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Xu Wang (X)

Department of Radiology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, 310022, Hangzhou, China.

Brett W Carter (BW)

Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Mara B Antonoff (MB)

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Jianhua Zhang (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Ara A Vaporciyan (AA)

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Harvey Pass (H)

Department of Cardiothoracic Surgery, New York University Langone Medical Center, New York, NY, 10016, USA.

Stephen G Swisher (SG)

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

John V Heymach (JV)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

J Jack Lee (JJ)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Ignacio I Wistuba (II)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Waun Ki Hong (WK)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

P Andrew Futreal (PA)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. afutreal@mdanderson.org.

Dan Su (D)

Department of Pathology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, 310022, Hangzhou, China. sudan@zjcc.org.cn.

Jianjun Zhang (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org.
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH